Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation

PURPOSE OF REVIEW: Inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) with denosumab is an effective treatment in a number of conditions including osteoporosis where suppression of bone resorption is desired. However, denosumab discontinuation is associated with rebound increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Albert S., Girgis, Christian M., McDonald, Michelle M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Osteoimmunology (A Pettit and J Charles, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718877/
https://www.ncbi.nlm.nih.gov/pubmed/36201122
http://dx.doi.org/10.1007/s11914-022-00756-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718877/
https://www.ncbi.nlm.nih.gov/pubmed/36201122
http://dx.doi.org/10.1007/s11914-022-00756-5

Ejemplares similares